AES-135
AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC50s ranging from 190-1100 nM[1].
Product Specifications
CAS Number
[2361659-61-0]
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AES-135.html
Concentration
10mM
Purity
98.21
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)(C)C1=CC=C(CN(C(CN(CC2=C(F)C(F)=C(F)C(F)=C2F)S(=O)(C3=CC=C(F)C=C3)=O)=O)C4=CC=C(C(NO)=O)C=C4)C=C1
Molecular Formula
C33H29F6N3O5S
Molecular Weight
693.66
References & Citations
[1]Shouksmith AE, et al. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem. 2019 Mar 14;62 (5) :2651-2665.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC11; HDAC3; HDAC6; HDAC8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1364131-01 0.02 mg (E-Coli)
Recombinant Encephalitozoon cuniculi V-type proton ATPase subunit B (VMA2)
Ask
View Details 
MBS1364131-02 0.02 mg (Yeast)
Recombinant Encephalitozoon cuniculi V-type proton ATPase subunit B (VMA2)
Ask
View Details MBS1364131-03 0.1 mg (E-Coli)
Recombinant Encephalitozoon cuniculi V-type proton ATPase subunit B (VMA2)
Ask
View Details MBS1364131-04 0.1 mg (Yeast)
Recombinant Encephalitozoon cuniculi V-type proton ATPase subunit B (VMA2)
Ask
View Details MBS1364131-05 0.02 mg (Baculovirus)
Recombinant Encephalitozoon cuniculi V-type proton ATPase subunit B (VMA2)
Ask
View Details